Literature DB >> 29212986

Effect of PEAR1 Genetic Variants on 1-Year Outcomes in Chinese Patients with Acute Myocardial Infarction After Percutaneous Coronary Intervention.

Yi Yao1, Xiao-Fang Tang1, Chen He1, Ying Song1, Jing-Jing Xu1, Xian-Min Meng1, Bo Xu1, Run-Lin Gao1, Jin-Qing Yuan1.   

Abstract

AIMS: Platelet endothelial aggregation receptor-1 (PEAR1) is a platelet transmembrane protein that plays an important role on platelet aggregation. The aim of this study was to investigate whether PEAR1 genetic variations are associated with 1-year outcomes in Chinese patients with acute myocardial infarction after percutaneous coronary intervention.
METHODS: A total of 647 consecutive Chinese patients with acute myocardial infarction that underwent percutaneous coronary intervention and that were exposed to standard dual antiplatelet therapy with aspirin and clopidogrel were enrolled in this study. Six single nucleotide polymorphisms of PEAR1 were detected using the ligase detection reaction method. The follow-up period was 12 months.
RESULTS: Overall, 66 (10.2%) adverse ischemic events occurred. Multivariate Cox regression analysis showed that carriage of the PEAR1 rs56260937 minor allele was an independent predictor of revascularization events (OR=2.15, 95% CI 1.12-4.15, p=0.022) after adjusting for confounding factors.
CONCLUSIONS: Genetic testing for PEAR1 variants can be helpful in predicting adverse ischemic events in Chinese patients with acute myocardial infarction after percutaneous coronary intervention.

Entities:  

Keywords:  Acute myocardial infarction; Outcome; Percutaneous coronary intervention; Platelet endothelial aggregation receptor 1; Polymorphism

Mesh:

Substances:

Year:  2017        PMID: 29212986      PMCID: PMC5945558          DOI: 10.5551/jat.39982

Source DB:  PubMed          Journal:  J Atheroscler Thromb        ISSN: 1340-3478            Impact factor:   4.928


  19 in total

1.  2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions.

Authors:  Glenn N Levine; Eric R Bates; James C Blankenship; Steven R Bailey; John A Bittl; Bojan Cercek; Charles E Chambers; Stephen G Ellis; Robert A Guyton; Steven M Hollenberg; Umesh N Khot; Richard A Lange; Laura Mauri; Roxana Mehran; Issam D Moussa; Debabrata Mukherjee; Brahmajee K Nallamothu; Henry H Ting
Journal:  Circulation       Date:  2011-11-07       Impact factor: 29.690

2.  Guidelines on myocardial revascularization.

Authors:  William Wijns; Philippe Kolh; Nicolas Danchin; Carlo Di Mario; Volkmar Falk; Thierry Folliguet; Scot Garg; Kurt Huber; Stefan James; Juhani Knuuti; Jose Lopez-Sendon; Jean Marco; Lorenzo Menicanti; Miodrag Ostojic; Massimo F Piepoli; Charles Pirlet; Jose L Pomar; Nicolaus Reifart; Flavio L Ribichini; Martin J Schalij; Paul Sergeant; Patrick W Serruys; Sigmund Silber; Miguel Sousa Uva; David Taggart
Journal:  Eur Heart J       Date:  2010-08-29       Impact factor: 29.983

3.  Effect of platelet receptor gene polymorphisms on outcomes in ST-elevation myocardial infarction patients after percutaneous coronary intervention.

Authors:  Jia-Hui Zhang; Jing Wang; Xiao-Fang Tang; Yi Yao; Yin Zhang; Yuan-Liang Ma; Bo Xu; Run-Lin Gao; Lei Song; Zhan Gao; Jue Chen; Yuan Wu; Yue-Jin Yang; Xian-Min Meng; Jin-Qing Yuan
Journal:  Platelets       Date:  2015-04-22       Impact factor: 3.862

Review 4.  Platelet-reactivity tests identify patients at risk of secondary cardiovascular events: a systematic review and meta-analysis.

Authors:  P P Wisman; M Roest; F W Asselbergs; P G de Groot; F L Moll; Y van der Graaf; G J de Borst
Journal:  J Thromb Haemost       Date:  2014-05       Impact factor: 5.824

5.  Polymorphisms associated with in vitro aspirin resistance are not associated with clinical outcomes in patients with coronary artery disease who report regular aspirin use.

Authors:  Deepak Voora; John Horton; Svati H Shah; Linda K Shaw; L Kristin Newby
Journal:  Am Heart J       Date:  2011-07       Impact factor: 4.749

6.  Association of PEAR1 genetic variants with platelet reactivity in response to dual antiplatelet therapy with aspirin and clopidogrel in the Chinese patient population after percutaneous coronary intervention.

Authors:  Yi Yao; Xiao-Fang Tang; Jia-Hui Zhang; Chen He; Yuan-Liang Ma; Jing-Jing Xu; Ying Song; Ru Liu; Xian-Min Meng; Lei Song; Jue Chen; Miao Wang; Bo Xu; Run-Lin Gao; Jin-Qing Yuan
Journal:  Thromb Res       Date:  2016-03-02       Impact factor: 3.944

7.  Genetic variation in PEAR1 is associated with platelet aggregation and cardiovascular outcomes.

Authors:  Joshua P Lewis; Kathleen Ryan; Jeffrey R O'Connell; Richard B Horenstein; Coleen M Damcott; Quince Gibson; Toni I Pollin; Braxton D Mitchell; Amber L Beitelshees; Ruth Pakzy; Keith Tanner; Afshin Parsa; Udaya S Tantry; Kevin P Bliden; Wendy S Post; Nauder Faraday; William Herzog; Yan Gong; Carl J Pepine; Julie A Johnson; Paul A Gurbel; Alan R Shuldiner
Journal:  Circ Cardiovasc Genet       Date:  2013-02-07

Review 8.  Novel targets for antithrombotic drug discovery.

Authors:  Nisha Nanda; David R Phillips
Journal:  Blood Cells Mol Dis       Date:  2006-02-13       Impact factor: 3.039

9.  PEAR1 attenuates megakaryopoiesis via control of the PI3K/PTEN pathway.

Authors:  Alexandre Kauskot; Christophe Vandenbriele; Sophie Louwette; Rik Gijsbers; Thomas Tousseyn; Kathleen Freson; Peter Verhamme; Marc F Hoylaerts
Journal:  Blood       Date:  2013-05-10       Impact factor: 22.113

10.  Targeted deep resequencing identifies coding variants in the PEAR1 gene that play a role in platelet aggregation.

Authors:  Yoonhee Kim; Bhoom Suktitipat; Lisa R Yanek; Nauder Faraday; Alexander F Wilson; Diane M Becker; Lewis C Becker; Rasika A Mathias
Journal:  PLoS One       Date:  2013-05-21       Impact factor: 3.240

View more
  5 in total

Review 1.  PEAR1 polymorphisms as a prognostic factor in hemostasis and cardiovascular diseases.

Authors:  Narges Ansari; Sahar Najafi; Saied Shahrabi; Najmaldin Saki
Journal:  J Thromb Thrombolysis       Date:  2021-01       Impact factor: 2.300

2.  The Management of Heavy Menstrual Bleeding After Percutaneous Coronary Intervention in a Woman of Reproductive Age.

Authors:  Zhi-Chun Gu; Fang-Hong Shi; Jie Zhu; Fang Wan; Long Shen; Hao Li
Journal:  Front Pharmacol       Date:  2019-01-15       Impact factor: 5.810

3.  Effect of CYP4F2 Polymorphisms on Ticagrelor Pharmacokinetics in Healthy Chinese Volunteers.

Authors:  Shanshan Nie; Kaifeng Chen; Chengxian Guo; Qi Pei; Chan Zou; Liangyuan Yao; Hongbo Yuan; Xia Zhao; Ran Xie; Xu He; Jie Huang; Guoping Yang
Journal:  Front Pharmacol       Date:  2022-02-25       Impact factor: 5.810

4.  Variants of PEAR1 Are Associated With Outcome in Patients With ACS and Stable CAD Undergoing PCI.

Authors:  Fabian Stimpfle; Maike Bauer; Dominik Rath; Elke Schaeffeler; Matthias Schwab; Meinrad Gawaz; Stefan Winter; Tobias Geisler
Journal:  Front Pharmacol       Date:  2018-05-15       Impact factor: 5.810

5.  Variation of PEAR1 DNA methylation influences platelet and leukocyte function.

Authors:  Benedetta Izzi; Francesco Gianfagna; Wen-Yi Yang; Katrien Cludts; Amalia De Curtis; Peter Verhamme; Augusto Di Castelnuovo; Chiara Cerletti; Maria Benedetta Donati; Giovanni de Gaetano; Jan A Staessen; Marc F Hoylaerts; Licia Iacoviello
Journal:  Clin Epigenetics       Date:  2019-10-29       Impact factor: 6.551

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.